Acromegaly is usually caused by a noncancerous tumor. Middle-aged adults are most commonly affected. Symptoms include enlargement of the face, hands, and feet. Prompt treatment is needed to avoid serious illness. Drugs can reduce the effects of growth hormone. If needed, surgery and radiation may be used to remove tumor cells.
This fantastic presentation by Dr. John Carmichael, Distinguished Professor of Clinical Medicine at the University of Southern California and Co-director of the USC Pituitary Center focuses on the controversies arising from the clinical dilemmas present in treating a complicated condition like acromegaly.
SAN FRANCISCO, BARCELONA, TORONTO – October 31, 2024 – Artificial Intelligence (AI) could play a significant role in aiding the diagnosis of rare diseases. This is especially true for facial recognition and machine learning in
From J D Faccinetti, co-founder – It is often said that once you know people with acromegaly, you will see it more often. It makes you wonder how apt the definition of “rare” is for
From the desk of Jorge D Faccinetti, co-founder: I can’t help but think that raising awareness for acromegaly would be easier with a different name. My branding instincts tell me that this name is doing
With the lead line of “There is more to my acromegaly than just numbers on a page” comes a new informational website from the Chiesi Global Rare Diseases patient support group. Rethink Acromegaly is a
Reading about each of these famous giants prompted me to dig a bit more to see if there was anything new to report on the genetics of pituitary adenomas. Here’s the latest.
Today’s podcast is about our super athlete friend Risa August and her new book about her acromegaly experience, her life, and her 1,800 mile ride from Canada to Mexico.
From J D Faccinetti, Co-founder and Chief Editor – When you deal with a chronic pituitary disease, you get close to your medications, just like you would to a friend. This was my experience with
Today, Dr. Scott Struthers talks to PWN about paltusotine, their new once-a-day oral drug candidate, which recently completed phase 3 of the clinical trial.
San Diego, California-based Crinetics Pharmaceutical announced today that its novel investigational drug paltusotine maintained IGf-1 levels in patients who switched from monthly injectables